Teknova Launches Underwritten Stock Offering Alongside Preliminary Q3 Beat
TKNO has more than doubled off its 52-week low of $1.91.
Summary
Teknova launched an underwritten common stock offering the same day it pre-announced Q3 revenue of $12.5M-$12.7M, up 19-21% year over year. Terms are not yet set, and the raise adds dilution on top of roughly $16.6M of cash at quarter-end.
Key Events · Financing and Capital Events · TKNO
-
Underwritten Common Stock Offering Launched
A preliminary prospectus supplement covers an underwritten offering of common stock, with share count and public offering price left blank pending pricing. TD Cowen and William Blair are joint book-running managers.
-
Pricing Reference and Over-Allotment
The last reported sale price was $6.80 on October 19, 2026. Underwriters hold a 30-day option to buy additional shares at the public offering price less discounts.
-
Cash Position and Use of Proceeds
Cash and short-term investments stood at about $16.6M at September 30, 2026. Proceeds are for general corporate purposes, potentially including repayment of a portion of the MidCap debt.
-
Same-Day Q3 Preliminary Results
Revenue is estimated at $12.5M-$12.7M (up 19-21% year over year), with gross margin of 36-38% and Adjusted EBITDA of negative $1.2M to negative $1.0M.
Analysis · TKNO · Life Sciences
Why it matters: Teknova is selling new common stock in an underwritten deal run by TD Cowen and William Blair, with the share count and price still blank in this preliminary supplement. The timing is deliberate—it lands the same evening the company pre-announced Q3 revenue of $12.5M-$12.7M (up 19-21% year over year) and gross margin of 36-38%, so management is raising into strength rather than distress. The balance sheet explains the urgency: cash and short-term investments were only about $16.6M at September 30 against an Adjusted EBITDA loss of roughly $1.0M-$1.2M for the quarter, so fresh equity extends the runway. The cost is dilution to existing holders at a price that will not be known until the deal prices; the last reported sale price was $6.80 on October 19, 2026. Proceeds are earmarked for general corporate purposes, potentially including paying down part of the MidCap debt, and a 90-day lock-up covers insiders. A separate $50M at-the-market sales agreement exists but cannot be used until a new prospectus is filed.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.1% of the 1524 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TKNO was trading at $6.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $396.8M. The 52-week trading range was $1.91 to $9.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.